Importantly, these studies demonstrate the effectiveness of RORA in treating both early-onset STGD and late-onset dry AMD, as mutations in ABCA4 are observed in both diseases [30–32, 39]. This evidence concerns the gene ABCA4 and dry age related macular degeneration.